entertainment
Eli Lilly said Tuesday that it will purchase DICE Therapeutics, a small company developing an experimental pill to treat psoriasis, for $2.4 billion in cash.
The deal price of $48 per share represents a 42% premium to DICE’s closing price Friday.
advertisement
“In combination with its novel technology and expertise in drug discovery, DICE’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases,” Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, chief customer officer, said in a statement.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
ProMED, early warning system on disease outbreaks, in peril
Next article： How to save PrEP access — and even expand it
Next article： How to save PrEP access — and even expand it
